Robin Wolz, PhD, IXICO, London, UK, shares his thoughts on the likely evolution of amyloid-PET usage with the introduction of blood-based biomarkers into clinical routine. A positive amyloid-PET result is well established as the gold standard for an Alzheimer’s disease (AD) diagnosis. While blood-based biomarkers are unlikely to outperform PET in terms of diagnostic accuracy, their cost effectiveness, availability, and non-invasiveness spotlights them as valuable pre-screening tools. However, some information cannot be obtained through blood-based biomarkers. As PET allows direct visualization of brain pathology, it gives information on regional build-up which is lost when looking at fluid markers. Dr Wolz stresses the importance of cooperative use for optimal outcomes. This interview took place at the CTAD 2023 conference in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
